{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "EU ORPHAN DRUG|Positive" in comments (approximate match)
Status:
Investigational
Source:
INN:atesidorsen [INN]
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Source:
NCT02658175: Phase 3 Interventional Completed Familial Chylomicronemia Syndrome
(2015)
Source URL:
Class:
NUCLEIC ACID
Status:
Designated
Source:
EU-Orphan Drug:EU/3/19/2171
Source URL:
Class:
NUCLEIC ACID
Status:
US Previously Marketed
Source:
TEGSEDI by AKCEA THERAPS
(2018)
Source URL:
First approved in 2018
Source:
TEGSEDI by AKCEA THERAPS
Source URL:
Class:
NUCLEIC ACID
Status:
US Approved Rx
(2016)
Source:
NDA208114
(2016)
Source URL:
First approved in 2016
Source:
NDA208114
Source URL:
Class:
POLYMER
Status:
US Approved Rx
(1996)
Source:
NDA020193
(1996)
Source URL:
First approved in 1996
Source:
NDA020193
Source URL:
Class:
POLYMER
Conditions:
Pentosan polysulfate sodium (brand name ELMIRON) is a low molecular weight heparin-like compound. It has anticoagulant and fibrinolytic effects and is indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. The mechanism of action of pentosan polysulfate sodium in interstitial cystitis is not known but was discovered, that it t binds Fibroblast growth factors (FGFs) as well as other heparin-binding growth factors.
Status:
Investigational
Source:
NCT02515838: Phase 2 Interventional Completed Sickle-Cell Disease
(2015)
Source URL:
Class:
POLYMER
Status:
Other
Class:
CONCEPT
Status:
Other
Class:
CONCEPT
Status:
Other
Class:
CONCEPT
